Biotechnology

Ernexa Therapeutics

Ernexa Therapeutics released FY2025 Q3 earnings on November 7, 2025 (EST), actual revenue USD 0, actual EPS USD -0.1507

Ernexa Therapeutics released FY2025 9 Months Earnings on November 7, 2025 (EST), actual revenue USD 0, actual EPS USD -3.064

Ernexa Therapeutics released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -2.6089

Ernexa Therapeutics released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -0.6076

Ernexa Hires Two Doctors for Ovarian Cancer and Autoimmune Disease Projects

Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Stock

Ernexa Therapeutics Inc. Completes Second Tranche of Private Placement Financing Raising $6 Million

Ernexa Therapeutics CEO Attends D. Boral Capital Conference

Ernexa Therapeutics released FY2025 Q1 earnings on May 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -2.3056

Ernexa Therapeutics Files Prospectus for 10.4M Share Sale

Eterna Therapeutics Renamed Ernexa Therapeutics, Shifting Focus to Product Development

Ernexa Therapeutics released FY2024 Annual Earnings on March 12 (EST), actual revenue USD 582 K (forecast USD 0), actual EPS USD -48.9723 (forecast USD -152.9999)

Ernexa Therapeutics released FY2024 Q4 earnings on March 12, 2025 (EST) with actual revenue of USD 1 K and EPS of USD -2.2552

Ernexa Therapeutics released FY2024 9 Months Earnings on November 12, 2024 (EST) with actual revenue of USD 581 K and EPS of USD -107.5451

Ernexa Therapeutics released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 487K, actual EPS USD -73.6952

Eterna Therapeutics Inc Signs Licensing and Collaboration Agreement with Factor Bioscience Limited

Ernexa Therapeutics released FY2024 Semi-Annual Earnings on August 13 EST with actual revenue of USD 94K and EPS of USD -33.7506

Ernexa Therapeutics released FY2024 Q2 earnings on August 13 (EST), actual revenue USD 47 K, actual EPS USD -15.3379

Ernexa Therapeutics released FY2024 Q1 earnings on May 14 (EST), actual revenue USD 47K, actual EPS USD -18.4297

Eterna Therapeutics to Present mRNA Engineered iPSC Series at ASGCT Annual Meeting

WeShop

Safe & Green

BLUE ACQUISITION CORP. ORD USD0.0001 CL A (SUBS/RTS) 11/06/2030

Semrush

PANTAGES CAPITAL ACQUISITION CORP. COM USD0.0001 A (SUBS/RTS) 15/11/2029

Nuvation Bio

STARRY SEA ACQUISITION CORP COM USD0.0001 (S/R 07/07/2030)

Haoxin

Caring Brands

Santech

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

CureVac BV

Rigel Pharma

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap